JDRF, the leading research and advocacy organization funding type 1 diabetes research announced today ViaCyte, Inc., a leading regenerative medicine company, has filed an Investigational New Drug application with the U.S. Food and Drug Administration seeking to initiate a Phase 1/2 clinical trial in patients with type 1 diabetes.
http://ift.tt/1mS0BjV
http://ift.tt/1mS0BjV
No comments:
Post a Comment